Home » Topics » Infection » HIV/AIDS

HIV/AIDS
RSS

Once-daily administration of RDEA-806 is safe and active against HIV in a phase II study

Aug. 8, 2008

AGS-004 immunogenic in HIV patients treated with antiretroviral therapy

Aug. 7, 2008

Discovery of new anti-HIV agents reported in recent patents

Aug. 5, 2008

Gilead and Merck & Co. sign agreement for HIV medication Atripla in 12 countries

Aug. 4, 2008

ImQuest receives SBIR grant from the NIAID to develop pyrimidinedione product in HIV

Aug. 1, 2008

Shionogi-GlaxoSmithKline starts phase IIa study with GSK-1349572 in HIV patients

Aug. 1, 2008

Merck & Co places development hold on HIV protease inhibitor PPL-100

July 30, 2008

Raltegravir clinically effective in a triple-class drug resistance HIV-1 infection

July 29, 2008

Novel HIV reverse transcriptase inhibitors named in recent Tibotec patent

July 28, 2008

Gilead initiates enrollment in phase III clinical trial of integrase inhibitor elvitegravir in HIV

July 24, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...